»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
°³¿ä
ÆûÆäº´ Ä¡·áÁ¦ ½ÃÀåÀº 2023-2028³â°£ 2¾ï 9,470¸¸ ´Þ·¯ È®´ëµÇ°í, ¿¹Ãø ±â°£ Áß ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 4.16%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÆûÆäº´ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´ë»óÀ¸·Î ÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ °ÔÀçÇß½À´Ï´Ù.
ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ°ú ÃËÁø¿äÀÎ, ½ÃÀå ȯ°æ Àüü¿¡ °üÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÆûÆäº´¿¡ °üÇÑ ÀÇ½Ä Çâ»ó ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ÆûÆäº´ ½Å»ý¾Æ ½ºÅ©¸®´× ÇÁ·Î±×·¥ È®´ë, ¸ÂÃãÇü ÆûÆäº´ Ä¡·á Á¢±Ù¿¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡ µî¿¡ ÀÇÇØ ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁسâ
2024³â
Á¾·á³â
2028³â
¿¹Ãø ±â°£
2024-2028³â
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
YOY 2024
3.69%
CAGR
4.16%
ÁõºÐ¾×
2¾ï 9,470¸¸ ´Þ·¯
º» Á¶»ç¿¡¼´Â ÇâÈÄ ¸î ³â°£ ÆûÆäº´ Ä¡·áÁ¦ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿äÀÎ Áß Çϳª·Î¼ ÆûÆäº´ Ä¡·á ½Å¾à ½ÂÀÎÀ» µé°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Áø´ÜÀÇ ¹ßÀü°ú Èñ±ÍÁúȯ Ä¡·á¿¡ ´ëÇÑ Àü ¼¼°è ´ëó Áõ°¡´Â ½ÃÀåÀÇ ³ôÀº ¼ö¿ä·Î ¿¬°áµÉ °ÍÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå ±¸µµ
Á¦3Àå ½ÃÀå ±Ô¸ð
½ÃÀåÀÇ Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð(2023³â)
½ÃÀå Àü¸Á(2023-2028³â)
Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû
¼¼°èÀÇ ÆûÆäº´ Ä¡·áÁ¦ ½ÃÀå(2018-2022³â)
À¯Åë ä³Îº° ºÎ¹® ºÐ¼®(2018-2022³â)
Ä¡·á ºÐ¾ß ºÐ¼® 2018-2022
Áö¿ªº° ºÎ¹® ºÐ¼®(2018-2022³â)
±¹°¡º° ºÎ¹® ºÐ¼®(2018-2022³â)
Á¦5Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
¹ÙÀ̾îÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀï À§Çù
½ÃÀå ÇöȲ
Á¦6Àå ½ÃÀå ¼¼ºÐÈ : À¯Åë ä³Îº°
½ÃÀå ºÎ¹®
ºñ±³ : À¯Åë ä³Îº°
º´¿ø ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
¼Ò¸Å ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
¿Â¶óÀÎ ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
½ÃÀå ±âȸ : À¯Åë ä³Îº°
Á¦7Àå ½ÃÀå ¼¼ºÐÈ ¼¼¶óÇǺ°
½ÃÀå ºÎ¹®
ºñ±³ : ¼¼¶óÇÇ º°
È¿¼Ò ´ëü ¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
±âÁú °¨¼Ò ¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
½ÃÀå ±âȸ ¼¼¶óÇÇ º°
Á¦8Àå °í°´ »óȲ
Á¦9Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2028³â)
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦10Àå ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦ ¹× µ¿Çâ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå µ¿Çâ
Á¦11Àå º¥´õ ±¸µµ
°³¿ä
º¥´õ ±¸µµ
È¥¶õ »óȲ
¾÷°è ¸®½ºÅ©
Á¦12Àå º¥´õ ºÐ¼®
´ë»ó º¥´õ
º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
Amicus Therapeutics Inc.
Astellas Pharma Inc.
AVROBIO Inc.
Bayer AG
EpiVax Inc.
F. Hoffmann La Roche Ltd.
JCR Pharmaceticals Co. Ltd.
Johnson and Johnson
Maze Therapeutics Inc.
Sanofi SA
Á¦13Àå ºÎ·Ï
LSH
Abstract
The pompe disease drugs market is forecasted to grow by USD 294.7 mn during 2023-2028, accelerating at a CAGR of 4.16% during the forecast period. The report on the pompe disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing efforts to raise awareness regarding pompe disease, expanding newborn screening programs for pompe disease, and growing focus on personalized approach to pompe disease treatment.
Market Scope
Base Year 2024
End Year 2028
Series Year 2024-2028
Growth Momentum Accelerate
YOY 2024 3.69%
CAGR 4.16%
Incremental Value $294.7mn
Technavio's pompe disease drugs market is segmented as below:
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Therapy
Enzyme replacement therapy
Substrate reduction therapy
Others
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the approval for new drugs for pompe treatment as one of the prime reasons driving the pompe disease drugs market growth during the next few years. Also, growing advancements in genetic diagnostics and global initiatives for treating rare diseases will lead to sizable demand in the market.
The report on the pompe disease drugs market covers the following areas:
Pompe disease drugs market sizing
Pompe disease drugs market forecast
Pompe disease drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pompe disease drugs market vendors that include Amicus Therapeutics Inc., Astellas Pharma Inc., AVROBIO Inc., Bayer AG, EpiVax Inc., F. Hoffmann La Roche Ltd., JCR Pharmaceticals Co. Ltd., Johnson and Johnson, Maze Therapeutics Inc., and Sanofi SA. Also, the pompe disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global Pompe disease drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global pompe disease drugs market 2018 - 2022 ($ million)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.3 Therapy Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Therapy Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel
6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ million)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)
7 Market Segmentation by Therapy
7.1 Market segments
Exhibit 48: Chart on Therapy - Market share 2023-2028 (%)
Exhibit 49: Data Table on Therapy - Market share 2023-2028 (%)
7.2 Comparison by Therapy
Exhibit 50: Chart on Comparison by Therapy
Exhibit 51: Data Table on Comparison by Therapy
7.3 Enzyme replacement therapy - Market size and forecast 2023-2028
Exhibit 52: Chart on Enzyme replacement therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Enzyme replacement therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Enzyme replacement therapy - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Enzyme replacement therapy - Year-over-year growth 2023-2028 (%)
7.4 Substrate reduction therapy - Market size and forecast 2023-2028
Exhibit 56: Chart on Substrate reduction therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Substrate reduction therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Substrate reduction therapy - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Substrate reduction therapy - Year-over-year growth 2023-2028 (%)
7.5 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Therapy
Exhibit 64: Market opportunity by Therapy ($ million)
Exhibit 65: Data Table on Market opportunity by Therapy ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Amicus Therapeutics Inc.
Exhibit 115: Amicus Therapeutics Inc. - Overview
Exhibit 116: Amicus Therapeutics Inc. - Product / Service
Exhibit 117: Amicus Therapeutics Inc. - Key offerings
12.4 Astellas Pharma Inc.
Exhibit 118: Astellas Pharma Inc. - Overview
Exhibit 119: Astellas Pharma Inc. - Product / Service
Exhibit 120: Astellas Pharma Inc. - Key news
Exhibit 121: Astellas Pharma Inc. - Key offerings
12.5 AVROBIO Inc.
Exhibit 122: AVROBIO Inc. - Overview
Exhibit 123: AVROBIO Inc. - Product / Service
Exhibit 124: AVROBIO Inc. - Key offerings
12.6 Bayer AG
Exhibit 125: Bayer AG - Overview
Exhibit 126: Bayer AG - Business segments
Exhibit 127: Bayer AG - Key news
Exhibit 128: Bayer AG - Key offerings
Exhibit 129: Bayer AG - Segment focus
12.7 EpiVax Inc.
Exhibit 130: EpiVax Inc. - Overview
Exhibit 131: EpiVax Inc. - Product / Service
Exhibit 132: EpiVax Inc. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 133: F. Hoffmann La Roche Ltd. - Overview
Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 135: F. Hoffmann La Roche Ltd. - Key news
Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus
12.9 JCR Pharmaceticals Co. Ltd.
Exhibit 138: JCR Pharmaceticals Co. Ltd. - Overview
Exhibit 139: JCR Pharmaceticals Co. Ltd. - Product / Service
Exhibit 140: JCR Pharmaceticals Co. Ltd. - Key offerings
12.10 Johnson and Johnson
Exhibit 141: Johnson and Johnson - Overview
Exhibit 142: Johnson and Johnson - Business segments
Exhibit 143: Johnson and Johnson - Key news
Exhibit 144: Johnson and Johnson - Key offerings
Exhibit 145: Johnson and Johnson - Segment focus
12.11 Maze Therapeutics Inc.
Exhibit 146: Maze Therapeutics Inc. - Overview
Exhibit 147: Maze Therapeutics Inc. - Product / Service
Exhibit 148: Maze Therapeutics Inc. - Key offerings
12.12 Sanofi SA
Exhibit 149: Sanofi SA - Overview
Exhibit 150: Sanofi SA - Business segments
Exhibit 151: Sanofi SA - Key news
Exhibit 152: Sanofi SA - Key offerings
Exhibit 153: Sanofi SA - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 154: Inclusions checklist
Exhibit 155: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 156: Currency conversion rates for US$
13.4 Research methodology
Exhibit 157: Research methodology
Exhibit 158: Validation techniques employed for market sizing
Exhibit 159: Information sources
13.5 List of abbreviations
Exhibit 160: List of abbreviations